What does this research mean for the field?

Greater annualized eGFR improvement with GLP-1 receptor agonists is associated with larger reductions in clinical heart failure events, indicating eGFR change may serve as a useful marker of heart failure benefit. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the relationship between estimated glomerular filtration rate (eGFR) changes and heart failure (HF) events in patients treated with GLP-1 receptor agonists.

April 15, 2026Open Access

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP ‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

Key Points

To investigate the relationship between estimated glomerular filtration rate (eGFR) changes and heart failure (HF) events in patients treated with GLP-1 receptor agonists.
Performed a meta-analysis of randomized controlled trials involving GLP-1 receptor agonists.

Structured PICO

Is annualised eGFR change associated with reductions in clinical heart failure events with GLP-1 receptor agonists?

Population

Patients in large-scale GLP-1 receptor agonist randomised controlled trials

Intervention

GLP-1 receptor agonists

Outcome

Clinical heart failure events and annualised eGFR change

Annualised eGFR change may serve as a useful marker of heart failure benefit with GLP-1 receptor agonists.

Abstract

Across large-scale GLP-1RA trials, greater annualised eGFR improvement was associated with larger reductions in clinical HF events. Annualised eGFR change may serve as a useful marker of HF benefit with GLP-1RAs.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Hasebe et al. (Mon,) studied this question.

synapsesocial.com/papers/69df2abce4eeef8a2a6afcd0 https://doi.org/https://doi.org/10.1111/dom.70749

Bookmark

View Full Paper